Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.
Dan Milczarski
Advertisement
Articles by Dan Milczarski
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Your Questions Answered: The Biggest Pharma and Biotech Stories This Week
3
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial
4
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
5